Exondys 51 was Sarepta Therapeutics’s largest revenue line in fiscal 2019, bringing in $380.72M of $380.83M (100%).
| Concentration Risk Benchmark | FY 2019 |
|---|---|
| Exondys 51 | $380.72M |
| Vyondys 53 | $115.00K |
| Total | $380.83M |
Sarepta Therapeutics brought in $380.83M from its two revenue lines in fiscal 2019, the year ended December 31, 2019. Exondys 51 was the largest at $380.72M (100.0%), ahead of Vyondys 53 at $115.00K (0.0%).
July 2010 Agreement (Ebola & Marburg Intravenous Administration) was Sarepta Therapeutics’s largest revenue line in fiscal 2014, bringing in $6.82M of $9.76M (70%).
| Lease Arrangement, Type | FY 2012 | FY 2013 | FY 2014 |
|---|---|---|---|
| July 2010 Agreement (Ebola & Marburg Intravenous Administration) | $36.56M | $9.06M | $6.82M |
| August 2012 Agreement (Intramuscular Administration) | $673.00K | $2.79M | — |
| European Union Skip-Nmd Agreement (Dmd) | — | $1.26M | $1.43M |
| Carolinas Medical Center Agreement (Dmd) | — | — | $850.00K |
| Children's National Medical Center Agreement (Dmd) | — | $674.00K | $659.00K |
| June 2010 Agreement (H1N1/Influenza) | — | $427.00K | — |
| Other Agreements | $99.00K | — | — |
| Total | $37.33M | $14.22M | $9.76M |
Sarepta Therapeutics brought in $9.76M from its four revenue lines in fiscal 2014, the year ended December 31, 2014. Sarepta Therapeutics regrouped these revenue lines after fiscal 2013, so the total does not compare directly with that year's $14.22M. July 2010 Agreement (Ebola & Marburg Intravenous Administration) was the largest at $6.82M (69.9%), ahead of European Union Skip-Nmd Agreement (Dmd) at $1.43M (14.7%) and Carolinas Medical Center Agreement (Dmd) at $850.00K (8.7%). The remaining revenue line, Children's National Medical Center Agreement (Dmd), brought in $659.00K.
Compared with fiscal 2013, European Union Skip-Nmd Agreement (Dmd) grew fastest, up 13.4% to $1.43M, while July 2010 Agreement (Ebola & Marburg Intravenous Administration) fell the most, down 24.8% to $6.82M.
Sarepta Therapeutics began breaking out European Union Skip-Nmd Agreement (Dmd) in fiscal 2013, Carolinas Medical Center Agreement (Dmd) in fiscal 2014 and Children's National Medical Center Agreement (Dmd) in fiscal 2013. Sarepta Therapeutics stopped reporting August 2012 Agreement (Intramuscular Administration) ($2.79M in fiscal 2013), June 2010 Agreement (H1N1/Influenza) ($427.00K in fiscal 2013) and Other Agreements ($99.00K in fiscal 2012) as separate revenue lines.
July 2010 Agreement (Ebola & Marburg Iv) was Sarepta Therapeutics’s largest revenue line in fiscal 2011, bringing in $42.88M of $46.99M (91%).
| Parties To Contractual Arrangement | FY 2011 |
|---|---|
| July 2010 Agreement (Ebola & Marburg Iv) | $42.88M |
| June 2010 Agreement (H1N1) | $3.49M |
| May 2009 Agreement (H1N1) | $516.00K |
| Other Agreements | $109.00K |
| Total | $46.99M |
Sarepta Therapeutics brought in $46.99M from its four revenue lines in fiscal 2011, the year ended December 31, 2011. July 2010 Agreement (Ebola & Marburg Iv) was the largest at $42.88M (91.2%), ahead of June 2010 Agreement (H1N1) at $3.49M (7.4%) and May 2009 Agreement (H1N1) at $516.00K (1.1%). The remaining revenue line, Other Agreements, brought in $109.00K.
Sarepta Therapeutics (SRPT) reports its revenue by concentration risk benchmark, by lease arrangement, type and by parties to contractual arrangement. In fiscal 2019, Exondys 51 was its largest revenue line, bringing in $380.72M (100.0% of the total), followed by Vyondys 53 at $115.00K (0.0%).
Exondys 51 was Sarepta Therapeutics' largest revenue line in fiscal 2019, bringing in $380.72M, or 100.0% of the $380.83M total across its two revenue lines.
Every figure comes from Sarepta Therapeutics' annual financial filings, as reported. Each line keeps the name Sarepta Therapeutics gives it, and years follow its fiscal calendar.
Sarepta Therapeutics' revenue by concentration risk benchmark goes back to fiscal 2019, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.